Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

27 July 2020: Database Analysis

Fibrinogen-Like Protein 2 (FGL2) is a Novel Biomarker for Clinical Prediction of Human Breast Cancer

Yanyan Feng 1AC* , Chunguang Guo 2BC* , Hesong Wang 1B , Lu Zhao 1CF , Wei Wang 1C , Ting Wang 1BC , Yuyin Feng 3C , Kai Yuan 1BCDF* , Guangrui Huang 3AEG*

DOI: 10.12659/MSM.923531

Med Sci Monit 2020; 26:e923531

Figure 3 Survival rates for FGL2 in breast cancer. The GEPIA database, PrognoScan database, and Kaplan-Meier plotter database were used to analyze the prognostic potential of FGL2 in breast cancer. (A) In the GEPIA database, a lower expression level of FGL2 was associated with a poor prognosis of disease-free survival (DFS) in breast cancer. (B–F) In the PrognoScan database, GSE9893, GSE3494, GSE4922, GSE2034, and GSE19615 were used to evaluate overall survival (OS), disease-specific survival (DSS), disease-free survival (DFS), and distant metastasis-free survival (DMFS), respectively. (G–I) The Kaplan-Meier plotter database was used to measure OS, relapse-free survival (RFS), and DMFS related to FGL2 in breast cancer.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750